Vera Therapeutics Stock Earns 'Moderate Buy' Rating from Analysts

Biotech firm's shares receive consensus recommendation from 12 research analysts

Apr. 16, 2026 at 6:34am

Got story updates? Submit your updates here. ›

An extreme close-up of highly detailed, metallic gears and machinery in shades of silver, gray, and black, conceptually representing the intricate financial infrastructure that powers the biotech industry.As Vera Therapeutics progresses its pipeline of autoimmune treatments, the company's 'Moderate Buy' rating from analysts signals growing confidence in its ability to navigate the complex financial and regulatory landscape of the biotech industry.Cambridge Today

Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing novel immunotherapies, has received a consensus 'Moderate Buy' rating from 12 equity research analysts covering the stock. The analysts have an average 12-month price target of $81.45 on Vera Therapeutics' shares.

Why it matters

Vera Therapeutics is a promising biotech firm working on innovative treatments for autoimmune and inflammatory diseases. The 'Moderate Buy' consensus rating and relatively high price target from Wall Street analysts suggest they see significant upside potential in the company's stock, reflecting confidence in the company's pipeline and future growth prospects.

The details

The 12 analysts covering Vera Therapeutics have issued ratings that include one 'Sell', one 'Hold', and ten 'Buy' recommendations. Bank of America, HC Wainwright, and The Goldman Sachs Group have all increased their price targets on Vera Therapeutics' stock in recent months, citing the company's progress in advancing its pipeline of Treg-selective cytokine therapies.

  • Vera Therapeutics' stock opened at $43.45 on Thursday, April 16, 2026.
  • The company reported its latest quarterly financial results on February 26, 2026.

The players

Vera Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing novel immunotherapies to treat autoimmune and inflammatory diseases.

Bank of America

A major Wall Street investment bank that has increased its price target on Vera Therapeutics' stock.

HC Wainwright

An investment banking and securities firm that has raised its price target on Vera Therapeutics' shares.

The Goldman Sachs Group

A leading global investment banking and securities firm that has lifted its price objective for Vera Therapeutics' stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

Investors will be closely watching Vera Therapeutics' progress as the company continues to advance its pipeline of novel immunotherapies. The stock's performance will likely be influenced by updates on the company's clinical trials and regulatory milestones.

The takeaway

Vera Therapeutics' 'Moderate Buy' rating from Wall Street analysts reflects the market's optimism about the company's potential to develop transformative treatments for autoimmune and inflammatory diseases. As the biotech firm continues to execute on its strategic priorities, its stock could offer attractive upside for investors willing to take on the risks associated with an early-stage clinical pipeline.